Glucocorticoids (GCs) have been shown to reduce insulin sensitivity in healthy individuals. Widely used in critical care to treat a variety of inflammatory and allergic disorders, they may inadvertently exacerbate stress-hyperglycaemia. This research uses model-based methods to quantify the reduction of insulin sensitivity from GCs in critically ill patients, and thus their impact on glycaemic control. A 
Introduction
Hyperglycaemia is prevalent in critical care [1] [2] [3] [4] [5] . Increased secretion of counter-regulatory hormones stimulates endogenous glucose production and reduces effective insulin sensitivity [3] [4] 6] . Studies by van den Berghe et al. [5, 7] , Krinsley [8] and Chase et al. [2] have shown that tight glucose control can reduce ICU mortality by 18-45%. Glucocorticoids are used in critical care to treat a variety of inflammatory and allergic disorders, but may exacerbate stress-hyperglycaemia through their side effect of reducing insulin sensitivity and may thus indirectly impact clinical outcome.
Studies have shown that glucocorticoids (GCs) increase insulin resistance (reduce insulin sensitivity) in healthy individuals [9] [10] [11] [12] [13] . However, there is a lack of data about whether this effect is equally valid, or equally large, for critically ill patients. Insulin resistance, defined by relatively low insulin-mediated glucose disposal, is common and can be extreme in critically ill patients, which makes tight glycaemic control (TGC) in intensive care unit (ICU) patients difficult. Treatment with GCs may therefore make this task even harder if they yield significant (further) reductions of insulin sensitivity. Model-based methods can readily quantify changes in the insulin resistance of critically ill patients where typical methods of assessing this metric may be difficult to apply.
Several studies have reported 30-62% decreases in insulin sensitivity of healthy subjects after shortterm administration of dexamethasone (2 or 6 mg/d) [9] [10] [11] [12] . Pagano et al. [13] documented a similar change with prednisone (15 mg/d). The mechanisms and pathways underlying these dramatic reductions in insulin sensitivity are not yet fully understood. Metabolic adaptations, including enhanced endogenous glucose production (EGP), increased plasma insulin concentrations, and reduced whole-body glucose disposal were also reported in these studies.
The primary hypothesis of this research is that insulin sensitivity is reduced by glucocorticoids in critically ill patients, but potentially to a lesser extent than in healthy individuals. Therefore, the aim of this research is to use model-based methods to quantify the effect of glucocorticoid therapy on insulin sensitivity of ICU patients and its impact on the resulting TGC interventions. These results will, for matched cohorts, enable assessment of whether GC therapy in the critically ill is detrimental to achieving tight glycaemic control, and thus potentially to patient outcome.
Materials and Methods

Subjects
This research was conducted as a retrospective study using records from 80 patients admitted to the Christchurch ICU between 2005 and 2007. A model-based measure of insulin sensitivity (S I ) was used to quantify changes between two matched, critically ill cohorts.
A cohort of 40 patients, who each spent 24 hours or more on the SPRINT glycaemic control protocol [2] and received glucocorticoid therapy during this time, was selected from the available records.
These patients had received treatment with one or more of the steroids listed in Table 1 . The perpatient median steroid dose was equivalent to 200mg/d of hydrocortisone [14] [15] [16] . Patients were excluded if they received β-blockers or ACE-inhibitors, as these therapeutics can affect glucose metabolism and insulin sensitivity in an opposing fashion [17] [18] [19] .
In cases where patients did not receive steroid therapy for the entire time they were on SPRINT, insulin sensitivity was considered to be affected by the drug for one effective biological half-life following the last dose. This period ensured that any effects of the exogenous glucocorticoids on insulin sensitivity had not reduced so far as to be undetectable or swamped by elevated levels of circulating endogenous cortisol, which is also common in critically ill patients [20] . However, this short period precludes useful comparison between on-and off-steroid insulin sensitivities within the cohort as exogenous glucocorticoids may have a significant effect on S I in some patients for longer than one half-life.
Relative potencies and biological half-lives of the glucocorticoids were based on data for antiinflammatory effects as these closely parallel the effects on glucose metabolism [16] . Table 1 lists the potencies and half-lives used in analysis of the steroids for this research. Table 1 . Glucocorticoids and their properties used in this study [14] [15] [16] .
A control cohort of 40 patients, who did not receive any glucocorticoid, β-blocker or ACE-inhibitor therapy, was also selected from patients on the SPRINT protocol. Patients were selected so that the overall cohort parameters (age, sex, outcome, severity of illness), shown in Table 2 , matched the steroid cohort as closely as possible. While the cohorts are matched for overall glycaemic levels, the control cohort had more time in the 4.0-7.0mmol/L glycaemia band than the steroid cohort.
The SPRINT protocol is a simple, lookup-table system derived from a model-based controller that modulates insulin and nutritional inputs. The protocol titrates insulin doses and nutrition rates to patient-specific insulin sensitivity for tight glycaemic control [2, [21] [22] . SPRINT 
Model-Based Insulin Sensitivity
This study used a model based on the clinically validated glucose-insulin models of Le Compte et al.
[23] and Lotz et al. [24] . The model-based insulin sensitivity has been shown to correlate well with the insulin sensitivity index (ISI) determined by the gold-standard hyperinsulinaemic-euglycaemic clamp (r > 0.90) [24] . Implementing this model in Matlab™ (Mathworks, Natick MA) with ICU patient data, an S I value was identified every hour for every patient while on the SPRINT protocol. In this way, 4,914 and 5,259 S I values were obtained for the steroid and control cohorts respectively.
The glucose-insulin system model is defined below and the model parameters, rates and constants are described in Tables 3 and 4 :
when C-peptide data is not available as in [24] . (7) Table 3 Glucose-insulin system model time varying parameters. Table 4 . Glucose-insulin system model population constant parameters.
Parameter Units Parameter description
S I (t) L/mU.min Model-fitted insulin sensitivity This model combines aspects from both Le Compte et al. [23] and Lotz et al. [24] . The glucose dynamics (Equation (1)) are very similar to those of Le Compte et al. [23] where G represents the absolute blood glucose value and there are separate endogenous glucose production (EGP) and central nervous system uptake (CNS) terms. With G representing absolute glycaemic level rather than the level above a basal set point as in Lotz et al. [24] , the model is more applicable for clinical use.
Experience with a large range of ICU patients has shown that it is difficult to identify a basal set point glucose level (G E ) in a clinical setting. The benefit of identifying G E is limited as it only affects the first term of (1), which does not have a large overall contribution owing to the small value of p G .
The insulin kinetics of Equations (2)- (3) were taken from the model of Lotz et al. [24] and have explicit terms for the major insulin clearance and diffusion pathways. Adding to the model of Lotz et al. [24] is the saturation term for receptor-bound insulin degradation in Equation (2). This term comes from the realisation that both the action and degradation of insulin bound to cellular receptors is saturable [25] . Equation (7) defines an endogenous insulin secretion term similar to Le Compte et al. [23] but suppressed by plasma insulin level rather than exogenous insulin delivery rate.
New to this formulation of the glucose insulin system model is the two compartment nutritional input model described by Equations (4)- (6). This model is based on the work of Worthington et al. [26] and Wong et al. [27] and ensures mass conservation of enterally delivered glucose.
Analysis
Non-parametric statistics (median, interquartile range) were used to define the location and spread of insulin sensitivity and blood glucose as typical distributions are asymmetric and skewed, rendering Gaussian statistics unsuitable [28] . Baseline variables were compared using the Mann-Whitney U test for continuous data or two-sided Fisher's exact test for categorical data. Insulin sensitivity values were compared using cumulative distribution functions (CDFs) and the Mann-Whitney U test for statistical significance. CDFs show the entire shape of the distribution, which is particularly useful for skewed data sets [29] . P-values of less than 0.05 were considered significant. 
Simulation Analysis
To quantify any clinically relevant effect of glucocorticoid-mediated changes in insulin sensitivity on blood glucose control and interventions under the SPRINT protocol, clinically validated virtual patient simulations [30] were conducted on the two study cohorts. The simulations used the glucose-insulin model with the SPRINT protocol controller and the identified insulin sensitivity profiles for each patient to generate a time course of expected glucose levels. These in-silico virtual patients have been reported to accurately represent clinical results [21, [30] [31] .
Increasing the insulin sensitivities of steroid cohort patients in simulation by 25 and 43% for the periods they received steroids effectively reverses glucocorticoid-mediated reductions to S I of 20 to 30% respectively. Similarly, reducing the S I of the control cohort by 20 and 30% for 70% of the time they spent on SPRINT simulated the effects of steroid administration on these control cohort patients for the proportion of their stay that is comparable to the steroids cohort. This simulation allows the impact of GCs on TGC and its interventions to be determined.
Results
Overall cohort analysis
Insulin sensitivity in patients receiving glucocorticoids was lower than control patients in an overall cohort comparison. Median insulin sensitivity was reduced 31% from 3.49x10 -4 to 2.40x10 -4 L/mU.min (p < 0.001). The CDF of insulin sensitivity of the steroid cohort is also shown for periods when the patients were not receiving steroid treatment for the purposes of comparison only. This data is primarily composed of insulin sensitivity values from periods after patients had completed glucocorticoid therapy (91% of off-steroid hours), so it is potentially biased by improved patient condition and thus may not make a fair comparison with on-steroids hours. In addition, the chosen on/off steroids cut-off point of one half-life means that some of this data may still be affected by exogenous glucocorticoids.
Percentile patient analysis
Analysis of the percentile patient data also shows a reduction at all likelihoods in insulin sensitivity for patients receiving glucocorticoids. Figure 3 In addition to reductions at the median likelihood, Figure 4 shows the distribution of differences between control and steroid percentile patient curves at each likelihood value (y-axis) for all percentile patients. All distributions are significantly different (indicated on the plot with '*'). All Tables 5 and 6 present the in-silico virtual patient simulation results for the steroid and control cohorts. Increasing the insulin sensitivities of steroid cohort patients in simulation by 25 and 43% (Table 5) for the periods they received steroids effectively reverses glucocorticoid-mediated reductions to S I of 20 to 30% respectively. Similarly, reducing the S I of the control cohort by 20 and 30% for 70% of the time they spent on SPRINT simulates the effects of steroid administration on these control cohort patients for the proportion of their stay that is comparable to the steroids cohort (Table 6 ). These results show that glucocorticoid-mediated changes in insulin sensitivity have limited impact on tight glycaemic control in the ICU setting in the context of the SPRINT protocol.
Simulation and Impact on TGC
Median blood glucose levels for both cohorts, and on a per-patient basis, changed by no more than 7% and remained well within the 4.0-7.0 mmol/L band. Percentage time in the 4.0-7.0 mmol/L band (TIB) also changed less than 10%, with no statistically significant differences in the per-patient distributions of TIB. As expected, more insulin and fewer carbohydrates were required for reduced S I and vice-versa. 
Discussion
Glucocorticoids cause significantly increased insulin resistance (significantly lower insulin sensitivity, S I ) in healthy individuals [9] [10] [11] [12] [13] . The aim of this research was to determine to what extent this effect occurs in critically ill patients, who are already relatively insulin resistant due to their condition, and how it may affect TGC. The results indicate that there is a reduction in insulin sensitivity in critically ill patients associated with the use of glucocorticoids.
In this study, a whole-cohort 31% reduction in median insulin sensitivity was seen between patients receiving glucocorticoids (during treatment) and the control cohort. Comparing the insulin sensitivities on a percentile patient basis confirms the results seen between cohorts. The median percentile patient, representative of a typical patient from the cohort, had a 25% reduction in median insulin sensitivity while receiving glucocorticoids. Figure 4 showed that statistically significant reductions in insulin sensitivity were associated with glucocorticoid treatment for all percentile patients.
Both the percentile patient and cohort analyses point to reductions in insulin sensitivity associated with glucocorticoid treatment of 20-30%. These figures are significantly less than the 30-62% reductions in insulin sensitivity reported in healthy subjects [9] [10] [11] [12] [13] . Differences in steroid dosages are unlikely to be responsible for the disparity as the patients in this study received higher equivalent daily doses (1.3-4.0 times larger) than the healthy subjects in these previous studies.
The dosage and particular drug received by patients in this study varied between individuals and over 
Physiological Rationale and Possible Causes
Although much research has been conducted on the effects of glucocorticoids on insulin sensitivity, very little is known about the specific mechanisms of action. Glucocorticoids reduce insulin sensitivity directly, as well as disrupting glucose metabolism at the liver, pancreas and peripheral tissues. Several studies have indicated that decreased cellular glucose uptake is at least partly responsible [13, [32] [33] .
Impaired intracellular glucose oxidation has also been shown to have a role in glucocorticoid induced insulin resistance [32] [33] . In addition, endogenous glucose production is enhanced by glucocorticoids [9, [12] [13] 34] , possibly through their enhancement of the synthesis and action of catecholamines [19, 32, [35] [36] .
Delaunay et al. [37] and Lambillotte et al. [38] showed that glucocorticoids suppress insulin secretion through a direct action on the pancreatic β-cells. However, the results from Binnert et al. [9] , Besse et al. [34] and Nicod et al. [12] show a clear increase in glucose-induced insulin secretion after administration of dexamethasone. It is possible that there are competing pathways with the net effect depending upon specific physiological conditions. In summary, critically ill patients have elevated levels of circulating cortisol and catecholamines due to their stress response [4, 39] . Any increase or enhancement of their action may have a reduced effect due to saturation of the physiological impact of these agents. For example, the increased hepatic glucose production associated with glucocorticoids may be blunted as it is already significantly enhanced due to the patients' condition. Healthy individuals, in contrast, typically have much lower levels of circulating catecholamines and cortisol. They would therefore show more significant reductions in S I and increases in EGP with additional, exogenous glucocorticoids than critically ill patients.
Limitations
A major limitation of using model-based methods is that the parameter of interest (S I ) is not measured directly and may be influenced by modelling errors or un-modelled effects. The insulin sensitivity parameter in the model used for this research captures the relative net effect of altered EGP, peripheral and hepatic insulin mediated glucose uptake and endogenous insulin secretion.
Therefore, increased EGP, reduced insulin mediated glucose uptake or reduced insulin secretion result in a decrease in effective S I captured by this model. Hence, glucocorticoid mediated changes to glucose metabolism, in addition to the direct effect on insulin sensitivity, cause a relative reduction in the model-based S I . While this model-based S I represents more of a "whole-body" insulin sensitivity, it still correlates very well (r > 0.90) with euglycaemic clamp derived insulin sensitivity, ISI [24] , providing support for this metric and overall analysis.
Conclusions
This research used model-based methods to show that glucocorticoids cause less of a reduction in the insulin sensitivity of critically ill patients than in healthy individuals. Both the percentile patient and cohort analyses point to reductions in insulin sensitivity associated with glucocorticoid treatment of 20-30%. These results are typically less than the 30-62% reductions in insulin sensitivity reported in healthy subjects, despite equivalent glucocorticoid doses in this study 1.3-4 times larger. This reduced suppression of insulin sensitivity in critically ill patients could be a result of saturation of the physiological impact of glucocorticoids due to already increased levels of catecholamines and cortisol common in critically illness. Virtual trial simulations showed that reductions in insulin sensitivity of 20-30% associated with glucocorticoid treatment in the ICU have limited impact on TGC, at least within the context of the SPRINT protocol.
